Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 08, 2024
Beyond bevacizumab: antiangiogenic agents.
Journal: Clinical lung cancer
Published: September 29, 2011
Showing 1-2 of 2
Last Updated: 09/26/2026